ResearcherUniversity of California San DiegoActive in the last 2 years
Shumei Kato
Matched on ORCID iD 0000-0003-1193-1815; OpenAlex author ID A5086626483. Sources: ClinicalTrials.gov.
Their work
- Papers
- 6 (first author 3, last author 1)
- Trials
- 1 (principal investigator on 1)
- Grants
- 0
- Labs led
- 0
- Collaborators
- 14
2013: 1 trial · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: 3 papers · 2022: none · 2023: 1 paper · 2024: 1 paper
Papers 6
- Pan-cancer analysis of TIM-3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity. Last author DOI 10.1002/cam4.6844↗
- Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis. First author DOI 10.1038/s41525-022-00346-5↗
- Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation. Co-author DOI 10.1002/onco.13758↗
- SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer. First author DOI 10.1172/jci.insight.150453↗
- Immune profiling and immunotherapeutic targets in pancreatic cancer. First author DOI 10.21037/atm-20-1076↗
- Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. Co-author DOI 10.1186/s13045-019-0824-4↗
Trials 1
- Study of Personalized Cancer Therapy to Determine Response and Toxicity Principal investigator NCT02478931↗
Closest collaborators
The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Razelle Kurzrock MD · 5 shared papers, 2019–2024 · strength 0.76
- Paper Pan-cancer analysis of TIM-3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient hetero… DOI 10.1002/cam4.6844↗
- Paper Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis. DOI 10.1038/s41525-022-00346-5↗
- Paper SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer. DOI 10.1172/jci.insight.150453↗
- Gregory P. Botta · 2 shared papers, 2021–2023 · strength 0.34
- Hitendra Patel · 2 shared papers, 2019–2023 · strength 0.29
- Jungah Lim · 1 shared paper, 2024 · strength 0.20
- Justin A. Shaya · 1 shared paper, 2023 · strength 0.19
- Hitendra Patel · 1 shared paper, 2021 · strength 0.15
- Ulka N. Vaishampayan · 1 shared paper, 2021 · strength 0.13
- Dana Backlund Cardin · 1 shared paper, 2021 · strength 0.13
- Patricia Mucci LoRusso · 1 shared paper, 2021 · strength 0.13
- Joseph W. Kim · 1 shared paper, 2021 · strength 0.13
- Steven R. Grossman · 1 shared paper, 2021 · strength 0.13
- Boris W. Kuvshinoff · 1 shared paper, 2021 · strength 0.12
- Carl Morrison · 1 shared paper, 2021 · strength 0.12
- Felicia L. Lenzo · 1 shared paper, 2021 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.